MedicaidPrior AuthMedium impact
Niktimvo™ (axatilimab-csfr) (New)
Humana·OH · Hematology, Oncology, Internal Medicine·Medicaid
Effective date
Jul 1, 2026
We identified it
Jul 2, 2026
Summary
Humana Medicaid (Ohio) has established a new prior authorization policy for Niktimvo™ (axatilimab-csfr), effective July 1, 2026. This intravenous medication for chronic Graft vs Host Disease (cGVHD) requires prior authorization and must meet three specific criteria: documented cGVHD diagnosis, failure of at least two prior systemic therapy lines, and patient weight of at least 40 kg. The billing team must implement prior authorization workflows before claims are submitted.
Action Required
By July 1, 2026: Billing team must implement prior authorization process for all Niktimvo (axatilimab-csfr) infusion claims submitted to Humana Medicaid (Ohio). Actions required: (1) Update billing system to flag all Niktimvo claims for mandatory prior authorization review; (2) Create authorization checklist requiring verification of: diagnosis code for cGVHD, documentation of at least two failed prior systemic therapy lines, and patient weight ≥40 kg; (3) Train providers and clinical staff to submit prior auth requests with required clinical documentation BEFORE administering the medication; (4) Configure system to deny or hold claims lacking prior authorization; (5) Reference www.humana.com/PAL for applicable medical and procedural coding information. Failure to obtain prior authorization before service delivery will result in claim denials by Humana Medicaid Ohio.